Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Molecular Medicine
  4. Volume 25, Issue 4
  5. Article
Volume 25, Issue 4
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

Invasive ductal carcinoma (IDC) is the most common type of breast cancer, primarily affecting women in the United States and across the world. This review summarizes key concepts related to IDC causes, treatment approaches, and the identification of biological markers for specific prognoses. Furthermore, we reviewed many studies, including those involving patients with IDC and ductal carcinoma (DCIS) that progressed to IDC. We reported various studies on the causes of IDC, including mutations on BRCA1 and BRCA2, different levels of expression of specific genes in signaling pathways, menopause status, alcohol consumption, aging, and hormone imbalances that cause IDC while p-SMAD4 expressions, DNA methylation, regulations of hub genes, and underestimation of IDC affecting prognoses. Prompt IDC diagnosis and early intervention have been reported to demonstrate a greater probability of eradicating IDC and preventing further recurrence in the future. It is crucial for physicians and researchers to equip patients with the best information possible to proactively manage their health, whether it be for IDC prevention or treatment. Overall, our review provided a comprehensive understanding of IDC that enables patients to grasp the nature of the disease with the hope of mitigating IDC risk, decrease the anxiety of a cancer diagnosis, and encourage patients to become more involved in making informed decisions for their healthcare.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240349468241113065031
2025-01-09
2025-06-23

  • From This Site

    /content/journals/cmm/10.2174/0115665240349468241113065031
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sunshine Women’s State Care. Available from: sunshinestatewomenscare.com/thsteps-of-a-self-breast-exam/ (accessed on 23-10-2024)
  2. MersinH. YıldırımE. GülbenK. BerberoğluU. Is invasive lobular carcinoma different from invasive ductal carcinoma?Eur. J. Surg. Oncol.200329439039510.1053/ejso.2002.1423 12711296
     [Google Scholar]
  3. American Cancer Society. Available from: cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy-side-effects.html (accessed on 23-10-2024)
  4. HartmannL.C. SellersT.A. FrostM.H. Benign breast disease and the risk of breast cancer.N. Engl. J. Med.2005353322923710.1056/NEJMoa044383 16034008
     [Google Scholar]
  5. Cleveland Clinic. Available from: http://www.my.clevelandclinic.org/health/diseases/23180-carcinoma (accessed on 23-10-2024)
  6. LesurfR. AureM.R. MørkH.H. Fritzman, B. Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer.Cell Rep.20161641166117910.1016/j.celrep.2016.06.051 27396337
     [Google Scholar]
  7. TamimiR.M. BaerH.J. MarottiJ. Comparison of molecular phenotypes of ductal carcinoma in situand invasive breast cancer.Breast Cancer Res.2008104R6710.1186/bcr2128 18681955
     [Google Scholar]
  8. ParkK.W. KimS.W. HanH. Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer.NPJ Breast Cancer202281810.1038/s41523‑021‑00364‑z 35031626
     [Google Scholar]
  9. BarettaZ. MocellinS. GoldinE. OlopadeO.I. HuoD. Effect of BRCA germline mutations on breast cancer prognosis.Medicine (Baltimore)20169540e497510.1097/MD.0000000000004975 27749552
     [Google Scholar]
  10. BrockE.J. JacksonR.M. BoernerJ.L. Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma.PLoS One2021165e025231410.1371/journal.pone.0252314 34048471
     [Google Scholar]
  11. HuA. HongF. LiD. KDM3B-ETF1 fusion gene downregulates LMO2 via the WNT/β-catenin signaling pathway, promoting metastasis of invasive ductal carcinoma.Cancer Gene Ther.202229221522410.1038/s41417‑021‑00301‑z 33828234
     [Google Scholar]
  12. SanliogluA.D. KorcumA.F. PestereliE. Trail death receptor–4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.Int. J. Radiat. Oncol. Biol. Phys.2007693716723
     [Google Scholar]
  13. CummingsS.R. TiceJ.A. BauerS. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk.J. Natl. Cancer Inst.2009101638439810.1093/jnci/djp018 19276457
     [Google Scholar]
  14. JordahlK.M. MaloneK.E. BagliaM.L. Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ.Breast Cancer Res. Treat.2022193247748410.1007/s10549‑022‑06573‑9 35347551
     [Google Scholar]
  15. ZhaoZ. ChenX. HaoS. Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer.Cytokine201789768110.1016/j.cyto.2016.09.012 27681506
     [Google Scholar]
  16. GomesC.C. Recurrent driver mutations in benign tumors.Mutat Res Rev2022789108441210.1016/j.mrrev.2022.108412
     [Google Scholar]
  17. C Ang D, Warrick AL, Shilling A, Beadling C, Corless CL, Troxell ML. Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.Mod. Pathol.201427574075010.1038/modpathol.2013.197 24186142
     [Google Scholar]
  18. MironA. VaradiM. CarrascoD. PIK3CA mutations in in situ and invasive breast carcinomas.Cancer Res.201070145674567810.1158/0008‑5472.CAN‑08‑2660 20551053
     [Google Scholar]
  19. LiuN. QiD. JiangJ. ZhangJ. YuC. Expression pattern of p Smad2/Smad4 as a predictor of survival in invasive breast ductal carcinoma.Oncol. Lett.20201931789179810.3892/ol.2020.11297 32194672
     [Google Scholar]
  20. HaoS. ZhaoY.Y. PengJ.J. Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis.Sci. Rep.20199128610.1038/s41598‑018‑36362‑8 30670771
     [Google Scholar]
  21. JohnsonK.C. KoestlerD.C. FleischerT. DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer.Clin. Epigenetics2015717510.1186/s13148‑015‑0094‑0 26213588
     [Google Scholar]
  22. WangY. LiangF. ZhouY. QiuJ. LvQ. DuZ. Sharp downregulation of hub genes associated with the pathogenesis of breast cancer from ductal carcinoma in situ to invasive ductal carcinoma.Front. Oncol.2021111163456910.3389/fonc.2021.634569 34094915
     [Google Scholar]
  23. BrennanM.E. TurnerR.M. CiattoS. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.Radiology2011260111912810.1148/radiol.11102368 21493791
     [Google Scholar]
  24. AbeH. HanasawaK. NaitohH. EndoY. TaniT. KushimaR. Invasive ductal carcinoma within a fibroadenoma of the breast.Int. J. Clin. Oncol.20049433433810.1007/s10147‑004‑0401‑9 15375712
     [Google Scholar]
  25. PoortmansP. Evidence based radiation oncology: Breast cancer.Radiother. Oncol.20078418410110.1016/j.radonc.2007.06.002 17599597
     [Google Scholar]
  26. RauscherG.H. JohnsonT.P. ChoY.I. WalkJ.A. Accuracy of self-reported cancer-screening histories: a meta-analysis.Cancer Epidemiol. Biomarkers Prev.200817474875710.1158/1055‑9965.EPI‑07‑2629 18381468
     [Google Scholar]
  27. World Health Organization. Guide to Early Cancer Diagnosis.2017Available from: https://www.who.int/publications/i/item/9789241511940 (accessed on 23-10-2024)
     [Google Scholar]
  28. Cancer Treatment Centers of America. Available from: http://www.cancercenter.com/carcinoma (accessed on 23-10-2024)
  29. DongY. LiuS. ShenY. HeH. MaH. Probing variations of fibrous structures during the development of breast ductal carcinoma tissues via Mueller matrix imaging.Biomed. Opt. Express20201194960497510.1364/BOE.397441 33014593
     [Google Scholar]
  30. ChungH.L. TsoH.H. MiddletonL.P. SunJ. LeungJ.W.T. Axillary nodal metastases in invasive lobular carcinoma versus invasive ductal carcinoma: Comparison of node detection and morphology by ultrasound.AJR Am. J. Roentgenol.20222181334110.2214/AJR.21.26135 34319162
     [Google Scholar]
  31. John Hopkins Medicine.Invasive Ductal Carcinoma (IDC). Available from: http://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/invasive-ductal-carcinoma-idc (accessed on 23-10-2024)
  32. BrueningW. UhlS. FontanarosaJ. RestonJ. TreadwellJ. SchoellesK. Noninvasive Diagnostic Tests for Breast Abnormalities: Update of a 2006 Review. AHRQ Comp Eff Rev 2012; 2006. [Review. Agency for Healthcare Research and Quality]22420009
     [Google Scholar]
  33. SchuurE.R. Breast cancer: Molecular mechanisms, diagnosis, and treatment BT. In: International Manual of Oncology Practice: (iMOP)- Principles of Medical Oncology.Springer International Publishing2015
     [Google Scholar]
  34. StrangL.R. SunJ. SunW. Characteristics of microinvasive ductal carcinoma in situ versus noninvasive and invasive breast cancer.J. Surg. Res.202025437838310.1016/j.jss.2020.04.031 32535256
     [Google Scholar]
  35. SchnabelF. BoolbolS.K. GittlemanM. A randomized prospective study of lumpectomy margin assessment with use of margin probe in patients with nonpalpable breast malignancies - annals of surgical oncology.Ann. Surg. Oncol.20142014211589159510.1245/s10434‑014‑3602‑0 24595800
     [Google Scholar]
  36. Centers for Disease Control and Prevention. Available from: cdc.gov/genomics/disease/breast_ovarian_cancer/genes/_hboc.htm (accessed on 23-10-2024)
  37. PoggioF. Del MastroL. BruzzoneM. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.Breast Cancer Res. Treat.2022191226927510.1007/s10549‑021‑06436‑9 34731351
     [Google Scholar]
  38. FarhatG.N. WalkerR. BuistD.S.M. OnegaT. KerlikowskeK. Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use.J. Clin. Oncol.201028355140514610.1200/JCO.2010.29.5121 21060026
     [Google Scholar]
  39. RuhstallerT. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: long-term follow-up of the BIG 1-98 Trial.J. Clin. Oncol.201937210511410.1200/JCO.18.00440
     [Google Scholar]
  40. ThorneloeR.J. HallL.H. WalterF.M. SideL. LloydK.E. SmithS.G. Knowledge of Potential Harms and Benefits of Tamoxifen among Women Considering Breast Cancer Preventive Therapy.Cancer Prev. Res. (Phila.)202013441142210.1158/1940‑6207.CAPR‑19‑0424 31988145
     [Google Scholar]
  41. RajendranS. SwaroopS.S. RoyJ. p21 activated kinase-1 and tamoxifen – A deadly nexus impacting breast cancer outcomes.Biochim. Biophys. Acta Rev. Cancer20221877118866810.1016/j.bbcan.2021.188668 34896436
     [Google Scholar]
  42. MaoC. YangZ.Y. HeB.F. Toremifene versus tamoxifen for advanced breast cancer.Cochrane Libr.201220212CD00892610.1002/14651858.CD008926.pub2 22786516
     [Google Scholar]
  43. LiY. DengZ. WangY. ShenS. Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study.Lipids Health Dis.2024231910.1186/s12944‑024‑02002‑6 38191454
     [Google Scholar]
  44. WangJ. XuB. WangW. ZhaiX. ChenX. Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.Breast Cancer Res. Treat.2018171353554410.1007/s10549‑018‑4867‑y 29974356
     [Google Scholar]
  45. KnudsenE.S. SchultzE. HamiltonD. Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center.Oncologist202227864665410.1093/oncolo/oyac089 35666660
     [Google Scholar]
  46. LiaoW. HuangJ. WuQ. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.Breast Cancer202027339940410.1007/s12282‑019‑01034‑6 31853795
     [Google Scholar]
  47. BidardF.C. KaklamaniV.G. NevenP. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.J. Clin. Oncol.202240283246325610.1200/JCO.22.00338 35584336
     [Google Scholar]
  48. BeumerJ.H. FoldiJ. Pharmacology and pharmacokinetics of elacestrant.Cancer Chemother. Pharmacol.202392215716310.1007/s00280‑023‑04550‑7 37314500
     [Google Scholar]
  49. MukherjeeA.G. WanjariU.R. NagarajanD. Letrozole: Pharmacology, toxicity and potential therapeutic effects.Life Sci.202231012107410.1016/j.lfs.2022.121074 36243120
     [Google Scholar]
  50. IwaseT. SajiS. IijimaK. Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor–positive breast cancer: AERAS, a randomized multicenter open-label phase iii trial.J. Clin. Oncol.202341183329333810.1200/JCO.22.00577 37079878
     [Google Scholar]
  51. CairnsJ. IngleJ.N. KalariK.R. Anastrozole regulates fatty acid synthase in breast cancer.Mol. Cancer Ther.202221120621610.1158/1535‑7163.MCT‑21‑0509 34667110
     [Google Scholar]
  52. Gómez Tejeda ZañudoJ. Barroso-SousaR. JainE. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.Nat. Commun.2024151244610.1038/s41467‑024‑45835‑6 38503755
     [Google Scholar]
  53. CheerS.M. PloskerG.L. SimpsonD. WagstaffA.J. Goserelin.Drugs200565182639265510.2165/00003495‑200565180‑00011 16392882
     [Google Scholar]
  54. MooreH.C.F. UngerJ.M. PhillipsK.A. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.N. Engl. J. Med.20153721092393210.1056/NEJMoa1413204 25738668
     [Google Scholar]
  55. OkarviS.M. Al-JammazI. Synthesis, Radiolabeling, and Preclinical Evaluation of 68 Ga/177 Lu-Labeled Leuprolide Peptide Analog for the Detection of Breast Cancer.Cancer Biother. Radiopharm.202237537238310.1089/cbr.2021.0370 35325547
     [Google Scholar]
  56. BauersfeldS.P. KesslerC.S. WischnewskyM. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.BMC Cancer201818147610.1186/s12885‑018‑4353‑2 29699509
     [Google Scholar]
  57. LesterS. CotranR.S. The breast. In: Cotran RS, Kumar V, Collins T, Eds, Robbins pathologic basis of disease.6th edPhiladelphia, PaWB Saunders Company199910931119
     [Google Scholar]
/content/journals/cmm/10.2174/0115665240349468241113065031
Loading
An Overview of Invasive Ductal Carcinoma (IDC) in Women’s Breast Cancer
Current Molecular Medicine 25, 361 (2025); https://doi.org/10.2174/0115665240349468241113065031
/content/journals/cmm/10.2174/0115665240349468241113065031
/content/journals/cmm/10.2174/0115665240349468241113065031
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): breast cancer; cancer treatments; carcinomas; DCIS; IDC; Invasive ductal carcinoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test